Clovis Oncology (NASDAQ:CLVS) shares are surging in today’s pre-market trade after its Rubraca demonstrated progression-free survival versus placebo for ovarian cancer.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
The company presented the data from the supporting ATHENA trial at the European Society of Medical Oncology (ESMO) Congress in Paris.
More details to follow…
Read full Disclosure
